Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands
- 20 January 2007
- journal article
- research article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 34 (2) , 173-183
- https://doi.org/10.1016/j.nucmedbio.2006.11.003
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Radiolanthanide-Labeled Monoclonal Antibody CC49 for Radioimmunotherapy of Cancer: Biological Comparison of DOTA Conjugates and 149Pm, 166Ho, and 177LuBioconjugate Chemistry, 2006
- Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphomaBlood, 2004
- Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-Labeled hLL2 (Epratuzumab) in Nude Mice with CD22-Positive LymphomaCancer Biotherapy & Radiopharmaceuticals, 2003
- Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant GliomasJournal of Clinical Oncology, 2002
- Synthesis of the First Diethylenetriaminepentahydroxamic Acid (DTPH) Bifunctional Chelating Agent,Bioconjugate Chemistry, 2002
- Tumor Therapy with Targeted Atomic NanogeneratorsScience, 2001
- In Vivo Comparison of CHX-DTPA Ligand Isomers in Athymic Mice Bearing Carcinoma XenograftsCancer Biotherapy & Radiopharmaceuticals, 1999
- Chimeric anti-tenascin antibody 81C6: Increased tumor localization compared with its murine parentNuclear Medicine and Biology, 1996
- Phase I studies of treatment of malignant gliomas and neoplastic meningitis with131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab?)2-a preliminary reportJournal of Neuro-Oncology, 1995
- Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascinJournal of Neuroimmunology, 1994